Oxford Biomedica PLC — Regulatory Filings 2015

Feb 16, 2015

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 0119F

Oxford Biomedica PLC

16 February 2015

Oxford BioMedica: Change of Registered Address

Oxford, UK - 16 February 2015: Oxford BioMedica plc (LSE: OXB), ("OXB" or "the Company") a leading gene and cell therapy company, announces that the registered office address of the Company has changed to:

Oxford BioMedica Plc

Windrush Court

Transport Way

Oxford

OX4 6LT

The registered address at Companies House has been changed with immediate effect.

-Ends-

For further information, please contact:
Oxford BioMedica plc: John Dawson, Chief Executive Officer Tim Watts, Chief Financial Officer	Tel: +44 (0)1865 783 000
Media Enquiries: Mary-Jane Elliott/ Matthew Neal/ Chris Welsh/ Laura Thornton Consilium Strategic Communications	Tel: +44 (0)20 3709 5700

Notes to editors

About Oxford BioMedica®

Oxford BioMedica plc (LSE: OXB) is a leading gene and cell therapy company with an unrivalled portfolio of gene therapy products in development and a platform of exclusive and pioneering technologies with which it designs, develops and manufactures unique gene-based medicines for some of world's largest pharmaceutical companies. Leveraging its proprietary LentiVector® IP and gene delivery system technology platform and unique tumour antigen (5T4), Oxford BioMedica is advancing its pipeline of seven gene therapy products addressing diseases for which there are currently no treatments or that are inadequately treated today, including ocular and central nervous system disorders. OXB Solutions, the Company's industry-leading manufacturing and development business, provides services to collaborators and partners working in gene and cell therapy, including Novartis and Immune Design Corp.  In addition, the Company has licenced products and IP to Sanofi, Pfizer, MolMed, Sigma-Aldrich, Biogen Idec, Emergent BioSolutions and ImaginAb. Further information is available at www.oxfordbiomedica.co.uk  and www.oxbsolutions.co.uk .

This information is provided by RNS

The company news service from the London Stock Exchange

END

CROGGUBWPUPAGGQ